|
1
|
Lacatusu GA, Vasilescu C, Mihai IF,
Filip-Ciubotaru F, Vata A and Manciuc C: COVID-19 and air
conditioning-is there an environmental link? Environ Eng Manag J.
19:1255–1260. 2020.
|
|
2
|
Manciuc C, Nemescu D, Vata A and Lacatusu
GA: SARS-CoV-2 infection and diabetes mellitus: A North Eastern
Romanian experience. Exp Ther Med. 21(279)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Docea AO, Tsatsakis A, Albulescu D,
Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou
M, Drakoulis N, et al: A new threat from an old enemy: Re-emergence
of coronavirus (Review). Int J Mol Med. 45:1631–1643.
2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tanasa IA, Manciuc C, Carauleanu A,
Navolan DB, Bohiltea RE and Nemescu D: Anosmia and ageusia
associated with coronavirus infection (COVID-19)-what is known? Exp
Ther Med. 20:2344–2347. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Calina D, Docea AO, Petrakis D, Egorov AM,
Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F,
Vinceti M, et al: Towards effective COVID-19 vaccines: Updates,
perspectives and challenges (Review). Int J Mol Med. 46:3–16.
2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Manciuc DC, Iordan IF, Adavidoaiei AM and
Largu MA: Risks of leptospirosis linked to living and working
environments. Environ Eng Manag J. 17:749–753. 2018.
|
|
7
|
Manciuc C, Dorobăţ C, Hurmuzache M and
Nicu M: Leptospirosis: Clinical and environmental aspects of the
Iaşi County. Environ Eng Manag J. 6:133–136. 2007.
|
|
8
|
Gisondi P, PIaserico S, Bordin C, Alaibac
M, Girolomoni G and Naldi L: Cutaneous manifestations of SARS-CoV-2
infection: A clinical update. J Eur Acad Dermatol Venereol.
34:2499–2504. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Marzano AV, Genovese G, Fabbrocini G,
Pigatto P, Monfrecola G, Piraccini BM, Veraldi S, Rubegni P, Cusini
MP, Caputo V, et al: Varicella-like exanthem as a specific
COVID-19-associated skin manifestation: Multicenter case series of
22 patients. J Am Acad Dermatol. 83:280–285. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Casas CG, Català A, Hernández GC,
Rodríguez-Jiménez P, Fernández-Nieto D, Lario ARV, Fernández IN,
Ruiz-Villaverde R, Falkenhain-López D, Velasco ML, et al:
Classification of the cutaneous manifestations of COVID-19: A rapid
prospective nationwide consensus study in Spain with 375 cases. Br
J Dermatol. 183:71–77. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Dominguez-Santas M, Diaz-Guimaraens B,
Abellas PG, Real CMG, Burgos-Blasco P and Suarez-Valle A: Cutaneous
small-vessel vasculitis associated with novel 2019 coronavirus
SARS-CoV-2 infection (COVID-19). J Eur Acad Dermatol Venereol.
34:e536–e537. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Manalo IF, Smith MK, Cheeley J and Jacobs
R: A dermatologic manifestation of COVID-19: Transient livedo
reticularis. J Am Acad Dermatol. 83(700)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Estébanez A, Pérez-Santiago L, Silva E,
Guillen-Climent S, García-Vázquez A and Ramón MD: Cutaneous
manifestations in COVID-19: A new contribution. J Eur Acad Dermatol
Venereol. 34:e250–e251. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Oakley AM and Krishnamurthy K: Stevens
Johnson Syndrome. In: StatPearls. StatPearls Publishing, Treasure
Island, FL, 2021.
|
|
15
|
Dutt J, Sapra A, Sheth-Dutt P, Bhandari P
and Gupta S: Stevens-Johnson syndrome: A perplexing diagnosis.
Cureus. 12(e7374)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore
L and Shear NH: Stevens-Johnson syndrome and toxic epidermal
necrolysis: An update. Am J Clin Dermatol. 16:475–493.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Abdelgabar A and Elsayed M: Case of
erythema multiforme/Stevens-Johnson syndrome: An unusual
presentation of COVID-19. J R Coll Physicians Edinb. 51:160–161.
2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Pudukadan D and John B: Toxic epidermal
necrolysis and coronavirus disease 2019: A rare association. J Skin
Sex Transm Dis. 3:184–187. 2021.
|
|
19
|
Shahraki T, Hassanpour K, Arabi A, Ansari
I and Sadoughi MM: Corona virus disease 2019-associated
Stevens-Johnson syndrome: A case report. BMC Ophthalmol.
21(274)2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rossi CM, Beretta FN, Traverso G,
Mancarella S and Zenoni D: A case report of toxic epidermal
necrolysis (TEN) in a patient with COVID-19 treated with
hydroxychloroquine: Are these two partners in crime? Clin Mol
Allergy. 18(19)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Narang I, Panthagani AP, Lewis M, Chohan
B, Ferguson A and Nambi R: COVID-19-induced toxic epidermal
necrolysis. Clin Exp Dermatol. 46:927–929. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tanaka A, Isei M, Kikuzawa C, Hinogami H,
Nishida K, Gohma I and Ogawa Y: Development of toxic epidermal
necrolysis in a coronavirus disease 2019 patient with recurrence of
positive SARS-CoV-2 viral RNA. J Dermatol. 48:e144–e145.
2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Besari AM, Lim JA, Vellaichamy PT, Hussain
FA, Kamaludin Z and Nor M: Stevens-Johnson syndrome as a primary
skin manifestation of COVID-19. Postgrad Med J.
20(140778)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Nassif A, Bensussan A, Boumsell L, Deniaud
A, Moslehi H, Wolkenstein P, Bagot M and Roujeau JC: Toxic
epidermal necrolysis: Effector cells are drug-specific cytotoxic T
cells. J Allergy Clin Immunol. 114:1209–1215. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chung WH, Hung SI, Hong HS, Hsih MS, Yang
LC, Ho HC, Wu JY and Chen YT: Medical genetics: A marker for
Stevens-Johnson syndrome. Nature. 428(486)2004.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Harr T and French LE: Toxic epidermal
necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis.
5(39)2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hazin R, Ibrahimi OA, Hazin MI and
Kimyai-Asadi A: Stevens-Johnson syndrome: Pathogenesis, diagnosis,
and management. Ann Med. 40:129–138. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Levy M and Shear NH: Mycoplasma pneumoniae
infections and Stevens-Johnson syndrome. Report of eight cases and
review of the literature. Clin Pediatr (Phila). 30:42–49.
1991.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Jawaro T, Kumar A, Pistun O and Dixit D:
Stevens-Johnson syndrome associated with chlordiazepoxide. J Pharm
Technol. 34:82–85. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
De Luca F, Losappio LM, Mirone C,
Schroeder JW, Citterio A, Aversano MG, Scibilia J and Pastorello
EA: Tolerated drugs in subjects with severe cutaneous adverse
reactions (SCARs) induced by anticonvulsants and review of the
literature. Clin Mol Allergy. 15(16)2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Techasatian L, Panombualert S, Uppala R
and Jetsrisuparb C: Drug-induced Stevens-Johnson syndrome and toxic
epidermal necrolysis in children: 20 years study in a tertiary care
hospital. World J Pediatr. 13:255–260. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Frey N, Bodmer M, Bircher A, Jick SS,
Meier CR and Spoendlin J: Stevens-Johnson syndrome and toxic
epidermal necrolysis in association with commonly prescribed drugs
in outpatient care other than anti-epileptic drugs and antibiotics:
A population-based case-control study. Drug Saf. 42:55–66.
2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Diphoorn J, Cazzaniga S, Gamba C,
Schroeder J, Citterio A, Rivolta AL, Vighi GD and Naldi L:
REACT-Lombardia study group. REACT-lombardia study group:
Incidence, causative factors and mortality rates of Stevens-Johnson
syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern
Italy: Data from the REACT registry. Pharmacoepidemiol Drug Saf.
25:196–203. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
34
|
Lerch M, Mainetti C, Beretta-Piccoli BT
and Harr T: Current perspectives on Stevens-Johnson syndrome and
toxic epidermal necrolysis. Clin Rev Allergy Immunol. 54:147–176.
2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Honma M, Tobisawa S, Iinuma S, Shibuya T,
Komatsu S, Takahashi I, Ishida-Yamamoto A and Iizuka H: Toxic
epidermal necrolysis with prominent facial pustules: A case with
reactivation of human herpesvirus 7. Dermatology. 221:306–308.
2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Peter J, Choshi P and Lehloenya RJ: Drug
hypersensitivity in HIV infection. Curr Opin Allergy Clin Immunol.
19:272–282. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yang CW, Cho YT, Hsieh YC, Hsu SH, Chen KL
and Chu CY: The interferon-γ-induced protein 10/CXCR3 axis is
associated with human herpesvirus-6 reactivation and the
development of sequelae in drug reaction with eosinophilia and
systemic symptoms. Br J Dermatol. 183:909–919. 2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Tagajdid MR, Doblali T, Elannaz H, Hammi
S, Belfequih B and Mrani S: Reactivation of cytomegalovirus in a
patient with Stevens-Johnson syndrome-toxic epidermal necrolysis.
Iran J Med Sci. 38 (2 Suppl):S195–S197. 2013.PubMed/NCBI
|
|
39
|
Richard EB, Hamer D, Musso MW, Short T and
O'Neal HR Jr: Variability in management of patients with SJS/TEN: A
survey of burn unit directors. J Burn Care Res. 39:585–592.
2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Bastuji-Garin S, Fouchard N, Bertocchi M,
Roujeau JC, Revuz J and Wolkenstein P: SCORTEN: A
severity-of-illness score for toxic epidermal necrolysis. J Invest
Dermatol. 115:149–153. 2000.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Papp A, Sikora S, Evans M, Song D,
Kirchhof M, Miliszewski M and Dutz J: Treatment of toxic epidermal
necrolysis by a multidisciplinary team. A review of literature and
treatment results. Burns. 44:807–815. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Miliszewski MA, Kirchhof MG, Sikora S,
Papp A and Dutz JP: Stevens-Johnson syndrome and toxic epidermal
necrolysis: An analysis of triggers and implications for improving
prevention. Am J Med. 129:1221–1225. 2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Di Stadio A, Ricci G, Greco A, de
Vincentis M and Ralli M: Mortality rate and gender differences in
COVID-19 patients dying in Italy a comparison with other countries.
Eur Rev Med Pharmacol Sci. 24:4066–4067. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Onder G, Rezza G and Brusaferro S:
Case-fatality rate and characteristics of patients dying in
relation to COVID-19 in Italy. JAMA. 323:1775–1776. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He
JX, Liu L, Shan H, Lei CL, Hui DSC, et al: China medical treatment
expert group for Covid-19: Clinical characteristics of coronavirus
disease 2019 in China. N Engl J Med. 382:1708–1720. 2020.PubMed/NCBI View Article : Google Scholar
|
